Posts Tagged ‘conflicts of interest’

Rep. Grijalva’s Requests and the Real Problem with Conflict of Interest Disclosure

On Tuesday, Arizona’s U.S. representative Raul Grijalva asked seven academics for their sources of funding and earlier drafts of testimony they have delivered before congressional committees. Since then, many have debated whether the requests cross the line into harassment or witch hunts or McCarthyism. Lost in the discussion around whether the requests are too broad is a bigger question to address: Why don’t we already know who funds the work of those who testify before Congress? Read More

Bookmark and Share

Who Should Decide What Happens When Scientists Violate Conflict of Interest Rules?

Scientists and institutions are under increasing scrutiny to be more transparent, especially when they publish research that has bearing on major public policy debates, and with good reason: funding can influence how studies are conducted and results are presented. It’s not easy though; when it comes to disclosure of conflicts of interest, practices vary across scientific disciplines, journals and institutions, and the lines regarding what should be disclosed are sometimes blurry. Read More

Bookmark and Share

We Found Independent Experts—the FDA Can Too

Pharmaceutical and medical device companies, and some in Congress, argue that it’s difficult to find independent experts to serve on FDA’s scientific advisory committees due to strong financial conflict of interest standards.

Our experience proves otherwise. Read More

Bookmark and Share

How Conflicted Experts Can Sway FDA Drug Approval Decisions: A Case Study on Yaz

Experts on FDA advisory panels with financial conflicts of interest can influence the approval of a drug in multiple ways, not only by voting to approve a drug but also by dominating the discussion and pressuring other panelists. In the case of the popular contraceptive drug Yaz, four scientists with financial conflicts of interest were enough to push the vote in favor of the drug, with significant consequences for some women. Read More

Bookmark and Share

The Human Cost of FDA Decisions: For a Midwestern Family, A Breakdown in Drug Safety Hits Home

The consequences of unsafe drugs and medical devices are real—and nobody knows that better than Gwen B. of West Sacramento, California. We talked a few days ago after she responded to a UCS action alert with a story about her mother, Maxine, and I was moved enough to want to share her family’s story with you. Read More

Bookmark and Share

Five Reasons Congress Should Support Strong Conflict-of-Interest Standards at FDA

As I’m sure you’ve noticed, we have been blogging quite a bit recently about the FDA. This corresponds to legislation that would determine how the FDA approves and monitors drugs and medical devices. But why have we been so focused on reducing the number of FDA advisory panel members who have financial conflicts-of-interest? Read More

Bookmark and Share

How the FDA Drug Approval Process Works

Earlier this week, my colleague Michael gave some general background on the Food and Drug Administration and what Congress has to do this year to ensure that the agency can continue to ensure the safety and efficacy of prescription drugs and medical devices. Read More

Bookmark and Share

For Drugs and Medical Devices, It’s Still a Jungle Out There

When UCS started looking at the use of science at the FDA several years ago, I sat down and read The Jungle, which has been credited with prompting President Theodore Roosevelt to establish the first iteration of the Food and Drug Administration more than a century ago. The grisly descriptions of the Chicago meat-packing industry still conjure up vivid images in my mind.

We’ve made great strides over the past century in protecting the public from unsafe food products. But it’s an entirely different part of the FDA’s wheelhouse that will be taking center stage over the next two months: the regulation of prescription drugs and medical devices. Read More

Bookmark and Share